Scott L. Burrows
Known title: Chief Financial OfficerCIK: 0001853327
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
Transaction History
| SYRE | ▲ Buy | Option Exercise | 7,500 | $109K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 600 | $53K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,500 | $135K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,100 | $193K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,071 | $285K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 229 | $21K | 10/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 17,500 | $254K | 9/30/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 17,500 | $1.6M | 9/30/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 18,232 | $1.6M | 9/2/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 7,500 | $109K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 900 | $78K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,016 | $177K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 4,384 | $382K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 200 | $18K | 9/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 7,500 | $109K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,100 | $486K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,300 | $221K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 100 | $10K | 8/3/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 7,500 | $109K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,775 | $506K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,725 | $152K | 7/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 15,000 | $218K | 6/25/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,000 | $436K | 6/25/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 10,000 | $871K | 6/25/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 7,500 | $109K | 6/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,801 | $126K | 6/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,599 | $184K | 6/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,100 | $223K | 6/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 12,500 | $181K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 12,500 | $892K | 5/1/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 7,500 | $109K | 4/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 6,200 | $305K | 4/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,300 | $65K | 4/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 200 | $8K | 3/3/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 2,500 | $36K | 3/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,300 | $93K | 3/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 18,428 | $300K | 9/2/2025 | View on chart |
| SYRE | ▼ Sell | Open Market | 18,531 | $522K | 9/3/2024 | View on chart |
| SYRE | ▲ Buy | Grant | 134,953 | $0 | 12/22/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 291 | $4K | 3/6/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 21,000 | $0 | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 18 | $297 | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 1,416 | $22K | 3/2/2023 | View on chart |
| ARQT | ▼ Sell | Open Market | 416 | $7K | 2/28/2023 | View on chart |
| ARQT | ▲ Buy | Option Exercise | 5,000 | $8K | 9/16/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 10 | $164 | 3/7/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 293 | $5K | 3/4/2022 | View on chart |
| ARQT | ▲ Buy | Grant | 13,300 | $0 | 3/3/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 420 | $7K | 3/1/2022 | View on chart |
| ARQT | ▼ Sell | Open Market | 12,560 | $252K | 12/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.